• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
ImmunoGen, Inc. - Product Pipeline Review - 2012 Product Image

ImmunoGen, Inc. - Product Pipeline Review - 2012

  • ID: 2233888
  • August 2012
  • 81 pages
  • Global Markets Direct

ImmunoGen, Inc. – Product Pipeline Review – 2012

Summary

Global Markets Direct’s pharmaceuticals report, “ImmunoGen, Inc. - Product Pipeline Review - 2012” provides data on the ImmunoGen, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ImmunoGen, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoGen, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ImmunoGen, Inc. - Brief ImmunoGen, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoGen, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment READ MORE >

2
List of Tables 5
List of Figures 6
ImmunoGen, Inc. Snapshot 7
ImmunoGen, Inc. Overview 7
Key Information 7
Key Facts 7
ImmunoGen, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
ImmunoGen, Inc. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products – Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
ImmunoGen, Inc. – Pipeline Products Glance 14
ImmunoGen, Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
ImmunoGen, Inc. – Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
ImmunoGen, Inc. – Drug Profiles 17
Cancer Program 1 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cancer Program 2 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Cancer Program 3 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
huHER3-8 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IMGN529 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
IMGN853 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
IMGN901 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IMGN901 + Carboplatin + Etoposide 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
IMGN901 + Revlimid + Dexamethasone 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SAR 566658 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ImmunoGen, Inc. – Pipeline Analysis 30
ImmunoGen, Inc. – Pipeline Products by Therapeutic Class 30
ImmunoGen, Inc. – Pipeline Products by Route of Administration 31
ImmunoGen, Inc. – Pipeline Products By Mechanism of Action 32
ImmunoGen, Inc. – Recent Pipeline Updates 33
ImmunoGen, Inc. - Dormant Projects 37
ImmunoGen, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
AVE1642 38
AVE1642 + Erlotinib 38
AVE1642 + Faslodex 38
AVE1642 + Sorafenib 39
AVE1642 + Velcade 39
AVE9633 39
IMGN242 39
IMGN388 40
ImmunoGen, Inc. – Company Statement 41
ImmunoGen, Inc. – Locations And Subsidiaries 44
Head Office 44
ImmunoGen, Inc. - Key Manufacturing Facilities 45
ImmunoGen, Inc., Recent Developments 46
ImmunoGen, Inc.- Press Release 46
Jul 11, 2012: ImmunoGen Initiates Phase I Trial Of IMGN853 In Ovarian Cancer And Other Solid Tumors Over-Expressing Folate Receptor Target 46
Apr 17, 2012: ImmunoGen Announces IND Application Now Active For IMGN853 46
Apr 17, 2012: ImmunoGen Initiates Phase I Trial Of IMGN529 In Non-Hodgkin's Lymphoma 47
Mar 30, 2012: ImmunoGen Initiates Phase II Evaluation Of IMGN901 In Small Cell Lung Cancer 48
Dec 06, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Multiple Myeloma 49
Nov 17, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Merkel Cell Carcinoma 50
Jul 31, 2009: ImmunoGen Announces Encouraging New Clinical Data With IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer 51
Jun 11, 2009: ImmunoGen, Inc. Announces The Discontinuation Of Further Internal Development Of Its IMGN242 Compound 52
Jun 01, 2009: Sanofi-Aventis Terminates Licensing With Immunogen For AVE 1642 52
Financial Deals Landscape 53
ImmunoGen, Inc., Deals Summary 53
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deal Details 54
Partnerships 54
ImmunoGen Enters Into Partnership With Novartis 54
Sanofi-Aventis Extends Research Collaboration With ImmunoGen 56
Licensing Agreements 58
ImmunoGen Extends Its License Agreement With Sanofi-Aventis 58
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 59
ImmunoGen Enters Into Second Licensing Agreement With Amgen 61
ImmunoGen Enters Into Licensing Agreement With Amgen 62
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology 63
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 64
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech 65
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis 67
ImmunoGen Enters Into Licensing Agreement With Biotest 68
ImmunoGen Extends Its Agreement With Millennium Pharma 69
Equity Offering 70
ImmunoGen Prices Public Offering Of Common Stock For $100 Million 70
ImmunoGen Completes An Underwritten Public Offering Of $84 Million 72
ImmunoGen Completes Public Offering Of $83 Million 74
ImmunoGen Completes Public Offering Of $40 Million 76
ImmunoGen Completes Private Placement Of $25 Million 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
ImmunoGen, Inc., Key Information 7
ImmunoGen, Inc., Key Facts 7
ImmunoGen, Inc. – Pipeline by Indication, 2012 10
ImmunoGen, Inc. – Pipeline by Stage of Development, 2012 11
ImmunoGen, Inc. – Monotherapy Products in Pipeline, 2012 12
ImmunoGen, Inc. – Combination Treatment Modalities in Pipeline, 2012 13
ImmunoGen, Inc. – Phase II, 2012 14
ImmunoGen, Inc. – Phase I, 2012 15
ImmunoGen, Inc. – Pre-Clinical, 2012 16
ImmunoGen, Inc. – Pipeline By Therapeutic Class, 2012 30
ImmunoGen, Inc. – Pipeline By Route of Administration, 2012 31
ImmunoGen, Inc. – Pipeline Products By Mechanism of Action, 2012 32
ImmunoGen, Inc. – Recent Pipeline Updates, 2012 33
ImmunoGen, Inc. - Dormant Developmental Projects,2012 37
ImmunoGen, Inc. - Discontinued Pipeline Products, 2012 38
ImmunoGen, Inc., Key Manufacturing Facilities 45
ImmunoGen, Inc., Deals Summary 53
ImmunoGen Enters Into Partnership With Novartis 54
Sanofi-Aventis Extends Research Collaboration With ImmunoGen 56
ImmunoGen Extends Its License Agreement With Sanofi-Aventis 58
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 59
ImmunoGen Enters Into Second Licensing Agreement With Amgen 61
ImmunoGen Enters Into Licensing Agreement With Amgen 62
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology 63
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 64
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech 65
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis 67
ImmunoGen Enters Into Licensing Agreement With Biotest 68
ImmunoGen Extends Its Agreement With Millennium Pharma 69
ImmunoGen Prices Public Offering Of Common Stock For $100 Million 70
ImmunoGen Completes An Underwritten Public Offering Of $84 Million 72
ImmunoGen Completes Public Offering Of $83 Million 74
ImmunoGen Completes Public Offering Of $40 Million 76
ImmunoGen Completes Private Placement Of $25 Million 78

List of Figures
ImmunoGen, Inc. – Pipeline by Indication, 2012 9
ImmunoGen, Inc. – Pipeline by Stage of Development, 2012 11
ImmunoGen, Inc. – Monotherapy Products in Pipeline, 2012 12
ImmunoGen, Inc. – Combination Treatment Modalities in Pipeline, 2012 13
ImmunoGen, Inc. – Pipeline By Route of Administration, 2012 31
ImmunoGen, Inc. - Pipeline Products By Mechanism of Action, 2012 32

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos